Natus Medical (NSDQ:NTUS) shares dipped today after the company lowered its 2020 sales guidance — even as it reported Q4 results met or slightly beat The Street.
The Pleasanton, Calif.-based maker of monitoring and diagnostics for newborns posted profits of $3.2 million, or 10¢ per share, on sales of $131.8 million for the three months ended Dec. 31, 2019, turning an $11.6 million loss in the same quarter last year into a profit on a sales decline of -6.6%.
Adjusted to exclude one-time items, earnings per share were 46¢, which were equal with the projections from Wall Street analysts. Revenue slightly beat the consensus on The Street.
Natus said that in 2020 it expects to log adjusted EPS of between $1.45 and $1.55. It lowered its 2020 sales guidance to between $480 million and $490 million, versus the previous guidance of $492 million to $496 million.
The company had lowered the high end of its yearly sales guidance during its previous quarterly earnings report.
NTUS shares were down -9.7% at $30.45 per share in midday trading today.
